POST Online Media Lite Edition


Revance names COO

Staff writer |
Newark, Ca., USA - December 16, 2015, Newark, Ca., USA - Revance Therapeutics, a specialty biopharmaceutical company, announced the appointment of Abhay Joshi as chief operating officer.

Article continues below

Dr. Joshi is a seasoned industry executive with nearly 30 years of global experience in biologics, pharmaceuticals, and medical devices, including extensive oversight of botulinum toxin research, development, and operations.

Dr. Joshi comes to Revance from Alvine Pharmaceuticals, Inc., a private, clinical-stage company focused on the development of biologics targeting autoimmune and inflammatory diseases, where he was President, Chief Executive Officer, and Director.

Prior to this, he was Chief Technical Officer and Executive Vice President at CoTherix, Inc. (acquired by Actelion Pharmaceuticals Ltd.), a biopharmaceutical company focused on licensing, developing, and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases.

Dr. Joshi began his career at Allergan, Inc. During his 18-year tenure at the company, he had increasing management responsibilities in pharmaceutical development, manufacturing, and global operations, rising to Vice President, Specialty Pharmaceuticals Operations, where he managed global biologics operations for the BOTOX product lines, and also managed Allergan’s Latin America and Asia Pacific pharmaceutical operations.


What to read next

Revance appoints director
Revance Therapeutics appoints Roman G. Rubio as SVP
BioTime adds Angus C. Russell to board of directors